Synergism between dipyridamole and cisplatin in human breast cancer cells in vitro

AUTOR(ES)

Perussi, Janice R., Paltoo, Dina N., Toppin, Veronica A. L., Canada, Robert G.

FONTE

Química Nova

DATA DE PUBLICAÇÃO

2003-05

RESUMO

Cisplatin is very effective in the treatment of metastatic breast cancer. However, the development of cellular resistance is a serious problem in cisplatin chemotherapy. In the present work, the effects of dipyridamole (DPM) on the cellular accumulation and cytotoxicity of cisplatin was studied in cisplatinsensitive (MDA/S) and cisplatinresistant (MDA/R) human breast cancer cells. In the presence of 30 µM DPM, the IC50 of cisplatin was reduced by 39% for both cell lines. Combination index analysis revealed that cisplatin and dipyridamole interact synergistically in MDA/R cells. In the MDA/S cells, the cellular accumulation of cisplatin increased by 57 ± 8% in the presence of 30 µM DPM. In the MDA/R cells, the cellular accumulation of cisplatin remained the same with or without 30 µM DPM. The results suggest that the enhancement of cisplatin cytotoxicity by DPM in MDA/S cells may be related to a DPM-induced increase in cisplatin accumulation, but the enhanced cytotoxicity in MDA/R cells employs a mechanism that does not involve an increase in the cellular accumulation of cisplatin.

Documentos Relacionados

• Dipyridamole increases the cytotoxicity of cisplatin in human larynx cancer cells in vitro
• Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells.
• Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase
• Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin
• Antagonism between Epidermal Growth Factor and Phorbol Ester Tumor Promoters in Human Breast Cancer Cells